Showing 4691-4700 of 5957 results for "".
- Oculus Receives FDA Clearance for the Myopia Masterhttps://modernod.com/news/fda-clearance-for-the-new-oculus-myopia-master/2479444/Oculus announced that it has received FDA 510(k) clearance for the Myopia Master, which combines axial length, refraction values, and the central corneal radii measurements. The quick, contactless measurement method for axial length is not influenced by the accommodation status of the eye
- Sydnexis Secures $45 Million Series B Financing to Advance Myopia Drug Candidatehttps://modernod.com/news/sydnexis-secures-45-million-series-b-financing/2479442/Sydnexis announced the completion of a $45 million Series B financing to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children. The financing was led by Visionary Ventures, Blue Stem
- Visus Therapeutics to Host First Capital Markets Day in New York Cityhttps://modernod.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/Visus Therapeutics announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue in New York City. During the Capital Markets Day, members of Visus’ leadership team and leading ey
- Oyster Point Pharma Announces License Agreement With Ji Xing Pharmaceuticals in Greater Chinahttps://modernod.com/news/oyster-point-pharma-announces-license-agreement-with-ji-xing-pharmaceuticals-in-greater-china/2479438/Oyster Point Pharma announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for the treatment of signs and symptoms of dry eye disease for patients in Greater Chi
- Rayner Announces 1,000 IOLs Recorded on RayPRO Digital Platformhttps://modernod.com/news/rayner-announces-1000-iols-recorded-on-raypro-digital-platform/2479436/Rayner announced that it has achieved the milestone figure of 1,000 intraocular lenses recorded on RayPRO, its digital patient reported outcomes platform. Launched at ASCRS in 2019 for ophthalmic surgeons who perform cataract procedures, RayPRO is a web-based and mobile digital platform th
- US Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry AMDhttps://modernod.com/news/us-phase-2-study-published-in-osli-retina-highlights-the-safety-and-efficacy-of-risuteganib-in-patients-with-dry-amd/2479429/Allegro Ophthalmics announced that the results of the company’s US phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina. Entitled
- Oculus Supports IMI in Raising Myopia Awarenesshttps://modernod.com/news/oculus-supports-imi-in-raising-myopia-awareness/2479430/Oculus has joined the International Myopia Institute (IMI) in tackling myopia awareness and will support the IMI activities to advance the research of myopia to prevent future vision impairment and blindness. “We are delighted about the cooperation. Our mission at Oculus is to support eye
- RxSight Announces Pricing of Initial Public Offeringhttps://modernod.com/news/rxsight-announces-pricing-of-initial-public-offering/2479423/RxSight announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16 per share. The gross proceeds to RxSight from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule-2/2479422/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Ocular Therapeutix Announces First Patient Dosed in US-Based Phase 1 Trial of OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-us-based-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2479421/Ocular Therapeutix announced that it has dosed the first patient in the United States phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (AMD). “We are very excited to have recently begu